Breast Cancer Coverage from Every Angle

Mafalda Oliveira, MD, PhD, on Clinical Implications of New Findings on Camizestrant in Advanced Breast Cancer

Posted: Thursday, January 5, 2023

Mafalda Oliveira, MD, PhD, of Spain’s Vall d’Hebron University Hospital and Institute of Oncology, discusses the apparent advantages of camizestrant, an oral selective estrogen receptor degrader, which improved progression-free survival in patients with hormone receptor–positive, HER2-negative breast cancer when compared with fulvestrant. Follow-up studies are already underway, combining camizestrant with a CDK4/6 inhibitor.

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.